Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in the u

The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progress

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus r

Top analysts changed outlook on top names. For all changes, see analyst ratings page. AVBP $47, PGR

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Bu

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and low

Guggenheim analyst Michael Schmitz reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and mai

BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains

Dimensional Fund Advisors LP lifted its stake in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) b

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(1.05) per share which missed the ana

NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent

Affinity Asset Advisors LLC lifted its position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP)

Truist Securities analyst Supawat Thongthip maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy

Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulat

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and low

$250,000,000Common StockWe have entered into an Open Market Sale AgreementSM (the sales agreement) w

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.96) per share which missed the ana

NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent)

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent)

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and rai

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommend

US stock futures rise, Vicor Corp shares dip 2.2% in pre-market trading after beating earnings and s

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investor

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in

Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed c

The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and

B. Riley Securities analyst Kalpit Patel maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy an

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant protein

NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVen

BTIG analyst Jeet Mukherjee assumes ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and annou

The average of price targets set by Wall Street analysts indicates a potential upside of 70.4% in Ar

Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their secto

Oppenheimer analyst Jeff Jones reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and rai

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Bu

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.78) per share which beat the analy

NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVen

ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given an average recommendation o

Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Leon Cooperman (Tra

Cantor Fitzgerald analyst Li Watsek initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a

BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy ratin

Truist Securities analyst Asthika Goonewardene initiates coverage on ArriVent BioPharma (NASDAQ:A

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and low

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.83) per share which missed the ana

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Bu

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and low

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.90) per share which missed the ana

HC Wainwright & Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:AVBP) with a B